Curadev, Roche partner to develop IDO1/TDO inhibitors for cancer

Curadev Pharma Pvt. Ltd. (New Delhi, India) and Roche (SIX:ROG; OTCQX:RHHBY) partnered to develop inhibitors of indoleamine 2,3-dioxygenase 1 ( IDO1) and tryptophan 2,3-dioxygenase ( TDO2; TDO) to treat cancer.

The deal gives Roche exclusive, worldwide rights to develop and commercialize Curadev's lead compound, CRD1152, which is a small molecule dual IDO1/TDO inhibitor. The Indian company will receive $25 million up front and is eligible for up to $530 million in milestones, plus escalating royalties up to double digits. Roche declined to say when it plans to start a clinical trial of CRD1152. ...